. 2012 Oct 25;21(4):987–992. doi: 10.1007/s00520-012-1617-2

Table 2.

Proportion of patients with hemoglobin decline from <10 g/dL to <9 g/dL

Patients or episodes with hemoglobin decline, % (95 % CI)	RCT patients^a	EMR episodes^b
Patients or episodes with hemoglobin decline, % (95 % CI)	Placebo (n = 411)	All episodes (n = 5,535)	Lung cancer episodes (n = 1,804)	Episodes with a platinum doublet (n = 3,489)
Week 3	40 % (35, 45)	35 % (34, 37)	42 % (40, 44)	40 % (38, 41)
Week 6	54 % (49, 59)	43 % (41, 44)	48 % (46, 51)	47 % (46, 49)
Week 9	58 % (53, 63)	46 % (44, 47)	51 % (49, 54)	51 % (49, 53)

^aValues represent Kaplan–Meier percentage estimates

^bValues represent crude percentages

RCT randomized controlled trials, EMR electronic medical records CI confidence interval